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Abstracts / Biol Blood Marrow Transplant 20 (2014) S57eS71S70(n¼3). Adult donors were HLA-matched related (n¼9), HLA-
matched unrelated (n¼7), HLA-mismatched unrelated
(n¼4). Conditioning was myeloablative in 22 patients and
reduced intensity conditioning in 6.
Results: All patients except one engrafted. The rate of
grade II-IV acute graft-versus-host disease (GVHD) at 100
days was 26% (95%CI 11-44%). The rate of chronic GVHD at
2 years was 8% (95%CI 1-24%). The cumulative incidence of
relapse/progression and non-relapse mortality at 2 years
was 8% (95%CI 1-22%) and 12% (95%CI 3-29%), respectively.
As of July 2013, with a median follow-up among survivors
of 26 months (range 2-134 months), 22 of 27 HCT re-
cipients were alive; 2 died of relapse, 1 of GVHD and 2 of
multiorgan failure. At 2 years, OS for patients receiving a
HCT was 80% (95% CI 58-91%) and PFS was 80% (95%CI 58-
91%) (Figure 1).
Conclusions: Our data indicate that HCT represents an
important salvage therapy associated with extremely favor-
able outcomes for patients with relapsed CBF AML and for
those with high risk features at presentation. Additional
studies in larger patient cohorts are needed to determine the
optimal transplant strategy for this group of patients.Table 1
Patient Characteristics n, (%)
Age, median (range), years 58 (26-73)
Patient 55 years of older 30 Patients (54.5%)
Gender 27 Female, 28 Male
Donor type
Unrelated donor (MUD) 39 (71%)
Related donor (RD) 16 (29%)
Conditioning Regimen
Bu4Flu (FIC) 36 (65%)
Bu2Flu (RIC) 19 (35%)
Status at transplant
CR1 36 (65%)
CR2 5 (9%)
PIF 14 (35%)
CIBMTR risk
Low 39 (71%)
Intermediate 4 (7%)
PIF 14 (22%)
Cytogenetic risk
Low 33 (60%)
High 22 (40%)
CR¼complete remission, PIF¼primary refractory
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Introduction: Reduced and full intensity conditioning (RIC,
FIC) regimens employing intravenous (i.v.) busulfan plus
ﬂudarabine (Bu-Flu) have resulted in improved treatment
related mortality and comparable overall survival in patients
undergoing allogeneic HCT for AML/MDS who are not can-
didates for more intense regimens. However, relapse after
HCT remains a leading cause of treatment failure after such
conditioning regimens.
Methods: In Order to assess relapse following allogeneic HCT
for AML/MDS , a retrospective analysis was performed to
evaluate the outcomes of 55 consecutive patients with AML/
MDS (49/6) who received i.v. Bu-Flu based conditioning.
Blood samples were collected post HCT in a subset of those
patients (30 patients). Serum values of 42 biological markers
were measured at day 30 post HCT (2/30 patients were day
60 samples) using multiplex Luminex assay. Patients
characteristic are shown in Table-1. Patients received single
daily dose of iv Bu 3.2 mg/kg for 2 days (RIC, Bu2-Flu) or 4
days (FIC, Bu4-Flu) based on age, older or younger than 65
respectively. Fludarabine was given as a single daily dose of
40 mg/Kg for 4 days. Graft versus host disease prophylaxis
was Tacrolimus/Methotrexate in FIC recipients and
Tacrolimus/Mycophenolate in RIC recipients. Low dose thy-
moglobulin of 4.5 mg/kg was used in unrelated donor HCT
recipients.
Results: With a median follow up of 18 month, the overall
survival (OS) at 1 & 2 years was 736% and 67  7%,
respectively, (Fig 1). Similarly, disease free survival at 1 and 2
years was 64  7%. As expected, there was low cumulativeincidence of treatment related mortality of 8  3% at 1 and
2 years while the cumulative incidence of relapse was 28.0 
3% and 31 2% at 1 and 2 years respectively, (Fig 2). Cumu-
lative incidence of grade II-IV acute GVHD was 54% with
grade III-IV of 25% at day 100. Cumulative incidence of
chronic GVHD was 49, 54% at 1 and 2 years respectively. In a
subset of patients where chemokine analysis was performed
(30 patients), only MCP-1 levels at day 30 post HCT were
predictive of relapse out of the 42 biological markers tested.
The 7 out of 30 patients who relapsed in this subset (23%)
had higher mean level of MCP-1 at day 30 of 537, SD 213
versus 324, SD  160, P¼0.007, (Fig 3). MCP-1 was predictive
of leukemic relapse 82 days in advance on average prior to
overt hematological relapse. Full chimerism (>95%) was
detected at Day 30 in 5/7 patients who relapsed in the bio-
logical marker group.
Conclusion: Bu-Flu based conditioning regimens result in
improved OS in patients with AML/MDS but do not impact
relapse rate after allogeneic HCT. Serum MCP-1 levels in the
early post-transplant period were predictive of relapse in
subset of patients where post HCT biomarkers were avail-
able. Future larger studiesmay ﬁnd potential role ofMCP-1 in
Fig 2.
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Background: Immunotherapy with T cells expressing
chimeric antigen receptors (CARs) has shown promise for
the immunotherapy of CD19+ malignancies in early clinical
studies. However, clinical efﬁcacy depends on signiﬁcant in
vivo expansion of adoptively transferred T cells, which can
be difﬁcult to achieve. Genetically modifying T cells with
bispeciﬁc T-cell engagers, which are able to recruit other T
cells locally, amplifying antitumor effects, could potentially
overcome this problem. Consistent and prolonged syn-
thesis of engagers by T cells should also be superior to the
intermittent direct infusion of the protein, both because
these molecules have short half-lives and do not accumu-
late at tumor sites. The goal of this project was to generate
T cells secreting CD19-speciﬁc T-cell engagers (CD19-ENG T
cells) and to evaluate their effector function in vitro and in
vivo.
Methods: A CD19-speciﬁc T-cell engager gene, consisting of
two single chain variable fragments speciﬁc for CD3
and CD19, was synthesized and subcloned into a SFG retro-
viral vector in front of an IRES and mOrange. CD19-ENG T
cells were generated by retroviral transduction and we
determined their effector function in coculture and cyto-
toxicity assays, and in the Ph+ ALL BV173/xenograft model.
Results: Post transduction 50-60% of T cells were positive for
transgene expression. In coculture assay CD19-ENG T cells
recognized CD19+ lymphoma (Daudi, Raji) and acute leuke-
mia (BV173) cells as judged by IFN-g and IL-2 secretion in
contrast to CD19- K562 cells. None of the targets were
recognized by non-transduced (NT) T cells or T cells secreting
engagers speciﬁc for an irrelevant antigen (EphA2-ENG T
cells). Antigen-dependent recognition was conﬁrmed in
standard cytotoxicity assays. In transwell assays containing
inserts that do not allow T-cell migration, only CD19-ENG
T cells redirected NT T cells in the bottom well to CD19-
positive tumor cells, demonstrating the ability of a diffusible
product from CD19-ENG T cells to redirect NT T cells to
CD19-positive tumor cells. To assess the anti-tumor activity
of CD19-ENG T cells in vivo we used BV173 cells that were
genetically modiﬁed with ﬁre ﬂy luciferase (ffLuc; ffLuc-
BV173) to allow for serial bioluminescence imaging. NSG
mice were injected iv with ffLuc-BV173 cells, and received an
iv dose of CD19-ENG or EphA2-ENG T cells and an ip dose of
IL2 on days 7, 14, and 21 post leukemia cell injection.
Untreated mice served as controls. CD19-ENG T cells had
potent anti-leukemia activity in contrast to EphA2-ENG T
cells resulting in a signiﬁcant survival advantage of treated
animals.
Conclusions: We have generated CD19-ENG T cells with the
unique ability to direct bystander T cells to CD19+ malig-
nancies. CD19-ENG T cells had potent anti-leukemia activity,
and may present a promising alternative to current
CD19-targeted immunotherapy approaches.
